y
-
-
-
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
-
Excerpt: The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. …
- ENDOCRINOLOGYOBSTETRICSPSYCHIATRY
Thyroid imbalance in pregnancy linked to increased likelihood of autism.
Persistent maternal thyroid dysfunctionโespecially when it spans multiple trimestersโsignificantly increases the risk of autism in children. A 2.68-fold rise in autism diagnoses was observed in cases where thyroid imbalance occurred …
-
This overview highlights emerging treatments for neovascular AMD, including new tyrosine kinase inhibitors and promising gene therapy programs. Clinical trials over the next two years may bring long-term, more durable …
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
Excerpt : Despite advances in technology, cardiovascular death rates remain stagnant. Interventional cardiologist Dr. Koushik Reddy argues for a radical paradigm shiftโmoving the foundation of care from the cath lab …
DERMATOLOGYIMMUNOLOGYRHEUMATOLOGY
Enpatoran delivers robust skin lupus efficacy across CLE and SLE, achieving high CLASI responses and early IFN suppression in WILLOW trial
by Chnfo@suni0
by Chnfo@suni0
The WILLOW trial reveals Enpatoranโs strong performance in mucocutaneous lupus, achieving high CLASI-50 and CLASI-70 response rates, remission milestones, and rapid IFN gene suppression in both CLE and SLE patients.